| Catalog No. | HB895026 |
| Brand | abinScience |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Isotype | IgG1-kappa |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | TNFR-I, Tumor necrosis factor receptor 1, Tumor necrosis factor receptor superfamily member 1A, TBPI, p60, CD120a, TNFRSF1A, Tumor necrosis factor receptor type I, p55, TNF-RI, TNFAR, TNFR1, TNF-R1 |
| References | 1. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010 Nov-Dec;2(6):639-47. [HB895026] 2. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. [HB895026] 3. E. Guenzi, et al. FRI0231 Atrosab, a humanized antibody directed against tnf-receptor 1, hold great promises for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2013 Jun 14; 72(3):A451. [HB895026] 4. Williams SK, et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep. 2018 Sep 11;8(1):13628. View More [HB895026] |
| Purification | Protein A/G purified from cell culture supernatant. |
| Biological activity | Atrosab (0.1-1000 nM, preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours) inhibits in a dose-dependent manner the TNF-induced apoptosis of Kym-1 cells [1]. Atrosab (0.1-1000 nM, preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours) inhibits release of IL-6 from HeLa cells and IL-8 from HT1080 cells induced by TNF dose-dependently [1]. Atrosab (100 ug/mL,24 h) reduces endothelial cell expression of adhesion molecules and T cell adhesion [3]. . Inhibited IL-6 release from HeLa cells with an IC 50 of 60 nM. Inhibited IL-8 release from HT1080 cells with an IC 50 of 60 nM. Atrosab (i.v., twice weekly, 28 days) has been shown to be effective for inflammatory diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) in both monkeys and human TNF transgenic/human TNFR1 knock-in mice model and in human TNFR1 knock-in mice (hp55K/i) EAE model [2]. Atrosab (20 mg/kg, i.p.) reduces immune cell infiltrates in humanized TNFR1 knock-in mice [3]. |
| Endotoxin level | < 10 EU/mg |
| Expression system | Mammalian cells |
| Accession | P19438 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternative name | ATROSAB |
| Clone ID | ATROSAB |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
Anti-Human TNF RI/TNFRSF1A Reference Antibody (ATROSAB, RUO)
Overview
Images
 SDS-PAGE |
SDS-PAGE for Research Grade Anti-Human CD120a/TNFRSF1A/TNFR1 (ATROSAB). |
 Bioactivity |
Detects Recombinant Human CD120a/TNFRSF1A Protein, C-His (Cat No.: HB895011) in indirect ELISA. |